Taxotere (docetaxel) is a chemotherapy drug approved in the treatment of certain cancers and is commonly used in the treatment of breast cancer.
Lawsuits have been filed against the manufacturer of Taxotere, Sanofi-Aventis, alleging that they failed to warn patients and physicians of the increased risks of permanent alopecia (loss of hair). Other chemotherapy drugs that did not cause permanent hair loss were available for use with similar or greater effectiveness.
Alopecia warnings were not added to the chemotherapy drug Taxotere in the U.S. until 2015, which was years after the drug came on the market. Many patients were not given a choice of an alternative to Taxotere even though there were other cancer drugs without similar side effects available.